Mental Health Startup Cerebral Admits Sharing Health Data With Facebook, Google, TikTok

Telehealth mental health startup Cerebral — after receiving a formal request from the federal government — admitted to sharing the private health information of more than 3.1 million patients in the United States with several advertisers and social media platforms.

According to the company’s “Notice of HIPAA Privacy Breach,” the data disclosed “varied depending on what actions individuals took on Cerebral’s Platforms, the nature of the services provided by the Subcontractors, the configuration of Tracking Technologies when the individual used our services, the data capture configurations of the Third-Party Platforms, how individuals configured their devices and browser, and other factors.”

Cerebral admitted to using tracking technologies since the company began operations in October 2019.

As TechCrunch reports: “Cerebral was sharing patients’ data with tech giants in real-time by way of trackers and other data-collecting code that the startup embedded within its apps. Tech companies and advertisers, like Google, Facebook, and TikTok, allow developers to include snippets of their custom-built code, which allows the developers to share information about their app users’ activity with the tech giants, often under the guise of analytics but also for advertising. But users often have no idea that they are opting-in to this tracking simply by accepting the app’s terms of use and privacy policies, which many people don’t read.”

In the company’s notice, Cerebral officials noted the tracking technologies were “disabled, reconfigured and/or removed,” and security practices and technology have been “enhanced.”

On Feb. 2 – in the wake of the Federal Trade Commission’s $1.5 million settlement with telehealth services provider GoodRX for allegedly disclosing patient health data to Facebook, Google, and other digital companies — Sens. Amy Klobuchar (D-Minn.), Susan Collins (R-Maine), Maria Cantwell (D-Wash.), and Cynthia Lummis (R-Wyo.) sent letters to leaders of telehealth companies requesting specific information regarding how they share consumer health data. Cerebral, Monument and Workit Health were among the companies contacted.

“Telehealth — an industry valued at over $30 billion — has become a popular and effective way for many Americans to receive care,” the senators wrote in the letter. “One-fifth of the U.S. population resides in rural or medically underserved communities where access to virtual care is vital. This access should not come at the cost of exposing personal and identifiable information to the world’s largest advertising ecosystems.”

Also, on March 3, Sen. Klobuchar, along with Sens. Elizabeth Warren (D-MA) and Mazie Hirono (D-HI) introduced legislation to expand protections for Americans’ personal health data privacy.

 

Source Link

Recommended Articles

P4ESC Warns Congress Not to Tax Health Benefits

“We oppose taxing health benefits,” said Neil Trautwein, P4ESC’s Executive Director. “Policymakers will find how widely unpopular the idea will be with Americans with this type of coverage if they take this unwise step,” added Trautwein.

Read More

At Social Security, These Are the Days of the Living Dead

In multiple instances over the past few weeks, Social Security Offices have seen people come in for whom “there is no information on the record, just that they are dead.” So employees have to “resurrect” them — affirm that they’re living, so they can receive their benefits.

Read More

Out-Of-Pocket Drug Spending Hit $98B In 2024: Report

Americans spent $98 billion out of pocket on prescription drugs in 2024, marking a cumulative 25% increase over five years, according to an annual report from analytics firm IQVIA. Why it matters: Lowering prescription drug costs remains a priority for both Democrats and Republicans. The Biden administration led Congress in passing a landmark legislative package to negotiate select drug ...

Read More

Trump Signs Executive Order To Encourage U.S. Drug Manufacturing

U.S. President Donald Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharmaceutical plants in the country, as part of new regulations to encourage domestic manufacturing. The order directs the U.S. Food and Drug Administration to streamline reviews and work with domestic manufacturers to provide early support ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square